figur reflect six month
oper subsequ year present
month quarterli figur figur australian dollar
burn offer shelter covid storm vitiligo
outpati drive lt outlook initi pt
initi coverag rcel outperform rate price target base
continu recel adopt burn market expect success clinic
trial recel treatment vitiligo trauma wound data
expand address market support recel sale
opportun pivot pipelin biotech cell therapi invest thesi assum
clinic data manufactur know-how serv potent long-term barrier
entri autolog cell therapi product recel furthermor view
expans outpati set offer potenti upsid obstacl rcel
commerci model view secur uniqu outpati reimburs code
next month critic mileston
competit primari autolog skin cell therapiesrecel
epicel skint believ recel posit
serv market tbsa wound focu tbsa base
eas use spray applic fast turnaround time attract cog
rcel eas use drive demand base discuss clinician recel
posit attribut includ limit donor site scar compar split-thick
graft fast applic good aesthet qualiti heal make recel
particularli attract use extrem expect introduc
recel intend improv outpati workflow requir lower
level nurse/technician support
revenu revenu model divid recel revenu
inpati burn scald trauma wound outpati vitiligo chronic
wound subset tbsa burn forecast recel revenu
inpati outpati
expect vitiligo account least half outpati sale inpati divid
burn trauma
burn offer shelter covid storm expect burn center
insul relat restrict hospital-bas servic
expect slowdown train new clinician modest declin
burn volum peopl stay home expect us recel launch one
med-tech growth stori endur headwind
rational pt view nt revenue burn center appropri
captur potenti valu vitiligo outpati set pt
base multipl sale full year vitiligo sale
discount back year includ econom eb
year price histori rcel
avita medic regen medicin
therapi recel treatment burn
dermatolog applic
also develop
system gene therapi treatment
analyst certif import disclosur see disclosur
view rcel pipelin expans stori built clinic
data recel new indic includ traumat wound
vitiligo believ manag effici de-risk
clinic develop pilot program expect on-going
valid studi readout serv basi
regulatori market catalyst total new
indic account recel
sale estim furthermor believ senior manag
prior cell therapi drug develop experi lay
groundwork second leg growth gene therapi
epidermolysi bullosa demonstr efficaci phase
expect signific re-valu rcel share
recel receiv outpati reimburs code
vitiligo traumat wound studi demonstr clinic benefit
econom contribut eb biotech pipelin
compani move domicil australia us end
domicil transit australia us
complet vitiligo dose find studi
complet traumat wound registr studi
complet vitiligo registr studi
outpati reimburs code implement
introduct recel
use recel dfu chronic wound
materi growth ex us revenu vs expect single-digit
partner deal eb program provid signific up-front payment
expans biotech product pipelin beyond eb program
dose find registr studi vitiligo fail demonstr
recel receiv reimburs code outpati set
allogen regen skin product enter market
gain sale momentum outpati set requir
commerci spend forecast
pt base ev-to-sal analysi assum multipl estim revenu second full year
vitiligo revenu discount back year divid million adr share outstand
risk rcel includ clinic accept recel altern autograft burn market clinic trial fail replic
pilot studi demonstr benefit recel treatment pediatr scald traumat wound chronic wound includ dfu pigment
loss associ vitiligo technolog obsolesc autolog regen skin product reduct drg reimburs
burn patient impact demand premium price product recel limit visibl futur clinic develop strategi
pipelin program includ cell therapi epidermolysi bullosa current cash balanc fund oper least
compani current receiv larg portion revenu outsid us potenti disrupt healthcar system econom
disloc relat infect transfer domicil australia us may complet end june
initi outperform pt
initi coverag avita medic ltd outperform rate price
target base continu adopt recel burn market expect
success outcom clinic trial recel treatment vitiligo trauma wound
expand address market support recel sale
intermediate-term opportun pivot pipelin biotech cell
therapi begin epidermolysi bullosa eb invest thesi assum clinic
data manufactur know-how serv potent barrier entri autolog cell
therapi recel allow rcel invest long-term market
develop limit risk direct competit
view expans outpati set offer biggest potenti upsid
obstacl rcel commerci model path outpati reimburs
insur compani uncertain treatment burn center drg
payment like requir direct negoti commerci payor expect
protract outpati reimburs process requir sustain invest howev
futur reimburs success like appli recel autolog cell
therapi may provid anoth layer protect potenti new entrant
model call rcel complet clinic trial dose-rang vitiligo trauma
wound respect follow complet vitiligo registr studi
fda clearanc expect recel enjoy second leg growth
begin recel revenu forecast inpati
indic tbsa burn trauma outpati market
pt base ev-to-sal multipl revenu usd
discount back four year million adr share
market segment limit direct competit autolog skin product
forecast assum limit direct competit three primari autolog
skin cell therapiesrecel epicel skint
believ recel posit serv market tbsa wound
focu tbsa base eas use spray applic fast turnaround
time rel epicel minut vs three week attract cog would
note tbsa account burn treat us accord american
burn associ term posit autolog skin cell therapi
expect epicel remain gold standard larg wound label intend use
tbsa base potenti produc larg sheet patient full thick
skin autograft alon option view skint best posit use
chronic wound market combin modal treatment burn
believ skint demonstr potenti produc high qualiti skin
inabl produc rapid steril cover may limit uptak burn patient primari
goal first creat steril environ prevent infect follow secondari
focu optim heal
posit feedback surgeon eas use
recel receiv pma approv fda intend use adult
partial thick burn tbsa base discuss clinician
use product posit attribut includ limit donor site scar compar
split-thick graft fast applic product good aesthet qualiti
heal make recel particularli attract use extrem expect
introduc recel intend improv workflow requir lower
level nurse/technician support view improv attract
recel sale potenti upsid outpati use
believ alreadi off-label use recel treatment acut trauma
wound mani burn center us also level trauma center
associ facil view distinguish demand trauma burn
patient becom increasingli difficult time revenu model divid
recel revenu inpati burn scald trauma wound outpati
vitiligo chronic wound subset tbsa burn forecast base
number train physician primari determin growth annual revenu per
surgeon annual inpati set total forecast recel
sale inpati outpati
pilot studi de-risk underappreci vitiligo trauma wound stori
view data plan valid studi recel use vitiligo essenti
support futur outpati reimburs coverag expand commerci
invest compani vitiligo pilot studi demonstr
patient report repigment view de-risk on-going us dose find
studi futur registr program limit prior data use recel
treatment chronic wound includ dfu vlu larg potenti
market underli comorbid make dfu vlu patient difficult treat
view rcel may year behind skint first autolog cell therapi
believ recel alreadi use label treatment trauma wound de-risk
on-going registr studi view primari question whether singl studi
enrol enough patient differ type trauma wound support broad
adopt use specif subset wound last includ pediatr
scald program conduct collabor barda revenu
forecast view pediatr scald limit market enrol pediatr studi
challeng
nearli autolog skin product launch burn market first base
potenti paid directli burn center drg payment
exist code autograft appli recel view reimburs
level code adequ support commerci return recel meet
sale forecast outpati sale forecast believ rcel
need receiv uniqu reimburs code view regulatori approv
repigment vitiligo patient one path gain attract separ reimburs
rate base absenc effect altern treatment repigment
prior join rcel ceo mike perri cso novarti cell gene
therapi believ background uniqu resourc offer opportun
compani build biotech product pipelin materi long-term upsid
includ cell therapi pipelin valuat believ move eb
program clinic develop could materi catalyst stock
thought
manag note burn center rel isol healthcar system
disrupt relat gener agre view expect
signfic slowdown train clinician begin fiscal risk enrol
target vitiligo trauma wound clinic trial
price target share rcel base primarili ev-to-sal
multipl project revenu discount back four year
view ev-to-sal appropri methodolog compani transit
sustain profit view gener compress valuat across
equiti market depress peer group valuat month pt assum
return normal peer group valuat rang
view direct publicli trade autolog cell therapi competitor
howev revenu heavili focus cartilag repair market rather
dermatolog indic view broad peer group biolog medic
product compani includ integra lifesci appropri
highlight exhibit autolog cell therapi biolog medic devic
compani trade mean multipl sale vs price target assumpt
rcel believ premium multipl normal
multipl justifi higher growth rate
factset oppenheim co inc estim
use base year ev-to-sal analysi base expect
rcel need month captur growth potenti vitiligo introduct
expand us sale forc
last view discount rate appropri rcel given limit visibl
outpati reimburs signific clinic trial risk support sale outlook
year revenu forecast multipl discount factor year equiti project dec share count share revenuerevenuemarkettech ev/price/segmenttickercompani estcapit valuerevenuesal ev/g medic lifesci nephew avita figur pro forma us regen cell therapi surgic medic instrument manufactur avita medic ltd
nearli medic devic compani quarterli sale updat like
materi catalyst rcel share discuss rcel expect transit
domicil australia us june begin report financi result
accord us gaap expect transit improv transpar rcel
oper perform market rcel stock us institut investor
addit view regulatori file potenti clearanc
recel primarili commerci mileston base increment improv
eas use less nurs support expect materi differ wound
heal perform next-gener devic forecast roll-out
uniqu code support outpati reimburs recel
term clinic catalyst view complet studi trauma injuri vitiligo
patient middl import catalyst expand address
market recel frame futur reimburs discuss see risk enrol
vitiligo studi delay due health system disrupt relat
expect may also impact time new site open trauma
wound studi patient continu treat hospit set
still candid potenti enrol increas risk patient may miss
follow visit assess safeti durabl heal
corpor histori busi model
compani form australia transit name avita medic
limit octob follow restructur direct invest
commerci recel initi approv australian tga-regist
european market ce-mark appoint current ceo mike
perri rcel complet larg us valid programtwo studi enrol
patientsand prepar entri us market fda issu pma clearanc
recel septemb intend use acut partial-thick thermal burn
wound applic combin mesh autograft acut fullthick
take expect substanti futur revenu growth come sale recel
us market limit growth australia europ japan
contract barda explor use recel treat thermal burn
import expand us infrastructur view govern contract
contribut growth current contract complet
eventtim importancefirst patient treat vitiligo studi compani us complet submiss recel vitiligo feasabl studi complet adult traumat injuri studi approv recel top-line data pediatr traumat injuri studi pediatr scald uniqu reimburs rcel outperform
current trade australian stock exchang ticker symbol avh
nasdaq nation market ticker rcel legaci headquart
melbourn austrlia execut team major employe
base near valencia california manag disclos plan transfer corpor
domicil australia us june
view rcel busi model depend medic product
compani gener clinic data secur reimburs develop
market autolog cell therapi condit tradit treat
off-the-shelf product manag investig use recel addit indic
includ trauma wound chronic wound vitiligo pediatr scald pediatr wound
exhibit view top line data studi import
potenti catalyst rcel share import benchmark shape futur
invest commerci infrastructur
view compani recent invest biotech cell therapi research
opportunist strategi leverag ceo mike perri prior experi cso novarti
cell therapi unit see potenti synergi avita spray devic
technolog expertis certain cell therapi program long term view cell therapi
offer limit synergi recel commerci oper
take eb cell therapi program demonstr clinic proof concept
potenti expect biotech cell therapi research activ spun
stand-alone compani
recel sold us field sale personnel consist regen tissu
specialist clinic train specialist region manag call burn center
lesser extent level trauma center
take us commerci organ like doubl next month
compani begin call outpati facil level trauma center
believ current commerci organ adequ support us burn center
recel point-of-car medic devic design regener keratinocyt fibroblast
melanocyt patient skin smaller donor site use
autograft cell harvest prepar step requir minut first skin
sampl minut subsequ sampl applic cell suspens
spray devic allow smooth distribut cell view potenti attract
rang partial thick dermatolog condit includ thermal burn scald
chronic wound includ dfu acut trauma wound vitiligo
take view eas use rel low cost requir small donor site
harvest primari point differenti particularli tbsa partial thick
trauma wound requir rel larg donor site autograft
reagent includ trypsin-bas recel enzym buffer disaggreg cell
spray devic deliveri regen epiderm suspens exhibit
exhibit present excerpt recel autolog cell harvest devic
inch mm depth packag insert recommend use graft
larger wound process requir collect four graft
clinic practic believ burn patient requir graft
take shallow mm graft complet quickli limit
scar compar tradit split thick skin graft
exhibit guid select skin sampl number size
goal enzymat mechan process disaggreg isol key
regen skin cell patient healthi donor site deposit
patient clean wound bed mani facil time consum
step process total minut howev prep time occur
surgeon prepar wound bed inpati burn recel prep time
rate limit step complet procedur exhibit
base avail public inform expect enzymat disaggreg
use potenti indic treatment vitiligo focus isol
exhibit enzymat mechan process
us recel devic produc approxim ml cover
healthcar provid deliv via spray drip method provid
basic overview applic step exhibit
stage enzymat incub skin test rins skin samplestag mechan process prepar scrape skin rins aspir filter suspens draw regen epiderm suspens avita medic ltd
recel outpati use
compani expect file regulatori approv recel support
potenti expans outpati market manag believ updat product
includ modif instrument need remain steril area
reduc number skill nurs requir complet
procedur provid appropri workflow outpati set
rcel disclos perform specif recel expect
sampl process time clinic outcom similar current devic
exhibit comparison recel recel
regulatori clearanc us eu australia
recel approv australia tga-regist european market ce-
mark gain us pma clearanc septemb base two
studi enrol patient believ recel current fda-clear point-
take given similar reagent devic use differ indic
expect process expand label intend use trauma chronic wound
vitiligo focus primarili complet addit clinic studi
current intend use us acut partial-thick thermal burn wound
applic combin mesh autograft acut full thick thermal burn
wound patient year age tbsa
devic contraind use infect necrot wound patient
hypersensit trypsin compound sodium lactat solut patient
hypersensit anesthet adrenaline/ epinephrin povidone-iodin chlorhexidin
stage deliv regen epiderm suspens prepar dress appli wound bed spray applic drip applic place dressingrecellrecel requir less personnel oper streamlin steril nonsteril area intuit learn use function ident rcel outperform
biolog wound heal
solut use recel contain mix popul cell includ
keratinocyt fibroblast melanocyt popul two outer layer skin
epidermi dermi exhibit keratinocyt fibroblast particularli import
regener new skin melanocyt regul fibroblast central
chouhan et al emerg innov approach wound heal skin regener current statu advanc biomateri
cutan injuri cascad biolog respons necessari restor barrier
function skin way background exhibit present overview
cell type role skin heal primari wound heal phase includ
inflammatori phase granul phase synthes new connect tissu
epitheli wound closur scar-remodel phase epiderm barrier
studi integr role keratinocyt fibroblast suggest keratinocyt
stimul fibroblast synthes growth factor induc
keratinocyt prolifer delay wound heal often due reduc keratinocyt
migrat prolifer furthermor keratinocyt involv fibroblast
cell populationdescriptionrol heal contact melanocyt epidermi fibroblast dermi may play role format patholog scar melanocyt best known pigment skin howev special skin cell produc protect skin-darken pigment melaninmelanocytea major cellular compon epidermismaintain barrier epidermi restor epidermi epitheli processkeratinocytefibroblasta spindle-shap cell oval flat nucleu found interstiti space organsfollow tissu injuri fibroblast migrat site damag deposit new collagen facilit heal process avita medic ltd
werner et al keratinocytefibroblast interact wound heal journal investig dermatolog
myofibroblast start appear granul tissu middl phase wound
heal process coincid strong induct contractil properti
align cell parallel mechan tension built granul tissu
align cell along tension line form basi restor connect tissu
role recel heal
addit deposit keratinocyt fibroblast recel believ speed
heal process melanocyt improv final appear skin scar-
exhibit heal process without recel
skin graft soc wound heal
current standard care partial thick wound surgic procedur
autograft transfer cutan tissu donor site anoth part
bodi donor site healthi section patient skin excis donor
site typic requir week heal valu autograft provid wound
protect environ pathogen temperatur excess water loss
creat environ foster heal skin graft blood suppli
must reli well-vascular wound bed heal
two form autograft split-thick skin graft stsg full-thick
skin graft ftsg stsg contain epidermi portion dermi ftsg
consist epidermi entir dermi exhibit
exhibit overview recel studi
gusman thornton skin graft skin substitut principl flap select read surgeri
stsg classifi accord thick thin stsg intermedi
stsg thick stsg recel requir thin stsg
follow applic skin graft undergo three step lead revascular
exhibit stage skin graft incorpor
braza fahrenkopf split-thick skin graft statpearl
skin graft requir multipl step support equip describ dr braza
fahrenkopf exhibit
stagedescript skin graft passiv absorb oxygen nutrient wound bed phase skin graft ischem surviv diffus alon reestablish graft vasculatur graft pale/whit time split-thick skin graft toler day ischemiaimbibitioninosculationa vascular network establish cut vessel undersid skin graft capillari bed wound bed establish vascular connect graft becom pink point inoscul typic occur around hour graft placementrevascularizationsever hypothes exist regard exact mechan revascular neovascular theori new vessel ingrowth graft recipi wound bed endotheli cell ingrowth theori suggest endotheli cell prolifer slide recipi site follow pre-exist vascular basal lamina structur graft endotheli cell eventu degrad rcel outperform
exhibit stage skin graft incorpor
braza fahrenkopf split-thick skin graft statpearl
take clinic success rate split-thick skin graft high indic
primari area unmet need met recel reduct size donor site graft
relat scar qualiti heal includ reduct scar wound site
potenti reduct cost time procedur vari wide depend specif
medic institut wound size
sever indic recel replac autograft
mention fda clear recel adult burn patient tbsa
howev compani either complet pilot program current conduct
studi sever indic includ stabl vitiligo trauma wound vlu dfu
pediatr scald pediatr skin deform exhibit
take revenu model invest thesi assum patient current
candid split-thick skin graft candid recel
procedureequipmentsplit-thick skin graft harvest sever way includ surgic knife oscil goulian knife commonli air electr power dermatom manual harvest uniform depth skin graft challeng may result irregular donor site well skin graft thu power dermatom frequent choic offer harvest consist well adjust graft thick order thousandth per inch width guard skin graft harvestmesh methodolog vari manual perfor skin graft surgic scalp hand-pow mesh devic mesher surgeon frequent util mesh devic applymultipl slit regular interv preset ratio commonli use ratio includ even split-thick skin graft get place mesher hand-crank machin mesh skin graftallow graft stretch increas area cover skin graft higher mesh ratio skin graft stretch howev longer take skin graft heal complet due increas area epitheli hole skin bridg act drainag hole prevent fluid blood seroma build-up recipi wound bed skin graft would caus graft failur skin graft meshingth stsg get secur recipi site skin stapl run simpl interrupt sutur applic skin stapl must faster sutur howev requir eventu remov stapl skin graft heal skin stapl appli regular interv around extent skin graft typic dissolv sutur like chromic util secur skin graft dissolv around time skin graft becom adher requir remov secur split-thick skin graft fast-clot fibrin glue high-concentr fibrin also report secur skin grafta tie bolster petroleum-infus gauz cotton ball non-dissolv sutur frequent place smaller stsg recipi site neg pressur wound vacuum anoth viabl option area difficult bolster case larg volum stsg petroleum-infus gauz bulki gauze/kerlix place graft graft left open air stsg donor site get cover petroleum-infus gauz clear adhes follow sever layer kerlix ace wrap altern donor site cover anti-microbi foam dress kerlix ace wrapdress avita medic ltd
exhibit overview recel studi
burn repres attract market earli adopt
recel clear fda use adult year age
burn casesin clinic practic expect product use patient irrespect
age base least part reimburs mechan specif us trauma
burn center typic receiv fix drg payment insur compani base
primarili wound size rcel supplier paid directli hospit
insur compani insur compani littl leverag
influenc product use inpati treatment
take inpati drg reimburs make burn market attract nich
opportun earli adopt
total popul patient hospit burn accord american burn
associ aba approxim peopl annual major patient
sever burn hospit burn center nearli bed exhibit
rcel estim burn surgeon us number burn
patient remain rel stabl past decad us
exhibit distribut burn center us record submiss aggreg
year aba publish detail analysi us burn market updat
includ data hospit across state major patient record come
hospit bed total patient admit
burn less tbsa patient mortal rate compar
mortal rate patient admit burn greater equal tbsa
breakdown total case mortal rate tbsa describ exhibit
exhibit patient surviv burn size
take roughli tbsa past decad target market
recel base inpati treatment wound signific opportun
reduc donor site graft
patient tbsa longer hospit stay tbsa vs
day higher hospit medic expens vs base
averag recel cost tbsa tbsa
estim recel expens total expens tbsa
tbsa
exhibit averag hospit total burn size
registr studi demonstr compar skin graft
compani complet registr studi recel
compar clinic perform split-thick mesh skin graft treatment
second degre burn subject age random receiv recel
control arm split-thick skin graft
tbsacas livedcas diedtot livedcas die rcel outperform
inclus criteria includ area burn injuri least tbsa
adult contigu wound least two non-contigu wound
total area tbsa subject exclud burn caus
chemic electr radioact substanc outsid tbsa rang
preexist condit counterind exhibit present overview final
holm et al compar studi recel devic autolog split-thick mesh skin graft treatment acut burn injuri journal burn
research
surgeon requir select two similar non-contigu injuri area area
least second degre depth/sever one wound area treat
recel treat use split-thick skin graft patient
random complet studi total five patient lost follow nine
exclud protocol violat
exhibit present overview primari secondari endpoint
exhibit overview primari secondari endpoint
outcomedefinit wound closur week base investig assess time frame week subject assess pain recel control donor site perform studi follow-up visit week also assess satisfact appear donor site week studi follow-up visit subject assess perform use va visual analogu scale style questionnair pain va pain pain appear va pain appear score donor subject assess time frame pain week appear week proport recipi site achiev wound closur week evalu use investig assess wound healingsubject assess pain recel control recipi site perform studi follow-up visit week also assess satisfact appear treatment site week studi follow-up visit subject assess perform use va visual analogu scale style questionnair pain va pain pain appear va assess pain recel control recipi site perform studi follow-up visit week also assess satisfact appear treatment site week studi follow-up visit subject assess perform use va visual analogu scale style questionnair pain va pain pain appear va pain appear score recel control recipi subject assess time frame pain week appear week primari endpoint recipi site wound closur recel stmsg defin presenc epitheli contigu layer viabl epithelium without need secondari surgic intervent factor consid assess includ color presenc granul tissu whether entir wound cover contigu layer viabl epithelium use definit small degre punctat blister accept long wound epitheli incid recell-tr area closur compar control week non-inferior donor site heal consid complet wound closur follow criteria met abil separ dress wound bed visibl presenc entireti wound dri opalescent-pink extern surfac repres newli form outer cornfield layer epidermi incid recel donor heal compar control week superior secondari endpoint percentag epitheli visit week time frame visit week percentag epitheli recel control treat site assess use standard planimetry/trac procedur trace upload central read facil calcul percent epitheli use computer measur techniqu rcel outperform
studi met primari endpoint noninferior recel split-thick skin graft
defin incid definit wound closur day exhibit specif
proport subject treatment site wound heal asc recel
control predefin noninferior margin achiev
noninferior confid interv
exhibit recel primari endpoint burn studi
holm et al compar studi recel devic autolog split-thick mesh skin graft treatment acut burn injuri journal burn
research
author disclos size donor site recel split-thick
skin graft studi captur incid donor site closur week
significantli better recel cohort exhibit
holm et al compar studi recel devic autolog split-thick mesh skin graft treatment acut burn injuri journal burn
research
furthermor studi met secondari endpoint wound site includ
differ pain visual appear scar asc recel
control split-thick skin graft exhibit interestingli metric
statist better wound site recel split-thick skin graft
take improv pain appear scar donor site highlight
improv patient experi recel compar split-thick skin graft
exhibit secondari endpoint assess treatment vs donor site
holm et al compar studi recel devic autolog split-thick mesh skin graft treatment acut burn injuri journal burn
research
barda studi highlight econom case recel
studi back offic assist secretari prepared respons
aspr barda kowal et al found financi burden use asc recel
less soc method treatment larger burn exhibit
averag save studi entitl cost-effect
use autolog cell harvest devic compar standard
treatment sever burn unit state
kowal et al cost-effect use autolog cell harvest devic compar standard treatment sever burn unit state
advanc therapi
burn may offer attract market term high cost treatment drg
reimburs structur see greater opportun clinician captur upsid
eas use rapid turnaround poc devic patient popul
trauma wound tiwari et al describ burn wound differ
wound indian journal surgeri extens burn excis usual occur
hour longer injuri burn stabil vs hour
trauma injuri view product turnaround time import treatment
larg address market trauma
base nation trauma databas ntdb annual report compil
leadership american colleg surgeon committe trauma acscot
approxim peopl hospit year us trauma injuri
treatment rel concentr level trauma center treat
patient exhibit total data collect hospit consist
level trauma center level ii trauma center level iv trauma center
pediatr level ii trauma center community/not specifi hospit
exhibit trauma facil level
american colleg surgeon committe trauma acscot nation trauma data annual report
take mani level trauma center co-loc burn center see
signific potenti commerci synergi exist burn center sale forc
expect rcel seek expand indic trauma wound view clinic data
person surgeon experi import drive uptak regulatori
rcel initi clinic studi support potenti expand indic
trauma wound patient expect top line data
take biggest challeng clinic studi trauma wound gener find
clinic practic due heterogen wound site sever injuri rang
march rcel open enrol onto studi
random control registr studi recel soft tissu reconstruct follow
trauma wound subject studi serv control
patient receiv autograft acut full thick wound exclud face
genitalia wound patient must two compar wound requir autograft
least surgeon also divid contigu area
studi design specifi maximum wound size maximum area
requir autograft must less tbsa subject age year younger
exclud studi patient whose wound result burn fail heal
follow surgic intervent also exclud studi qualifi injuri includ
deglov injuri crush injuri lacer skin surgic wound skin cancer cellul
infect necrot fasciiti gunshot wound
enrol site includ valleywis health arizona wake forest univers health
scienc north carolina driscol children hospit jp health network
take broad inclus criteria captur injuri associ rang
trauma wound unclear enrol larg enough support gener label
soft tissu reconstruct intend use limit specif wound type enrol
onto studi
patient receiv recel soc defin telfa clear xeroform wound
dress studi summari exhibit
co-primari endpoint confirm heal actual expans ratio within
week heal defin complet closur character skin re-
epitheli without drainag confirm two consecut studi visit least two
week apart actual expans ratio comput ratio measur treat area
measur donor site area calcul recel control includ donor
skin need secondari treatment
secondari endpoint includ patient observ scar assess scale posa
rate worst scale week subject
treatment prefer compar area week investig treatment
prefer compar area week
estim total patient inclus year tbsaexclus criteriaprimari confirm actual expans ratiossecondari posa patient observ scar assess scale subject treatment investig treatment prefer compar wound requir autograft least surgeon also divid contigu area qualifi injuri includ deglov injuri crush injuri lacer skin surgic wound skin cancer cellul infect necrot fasciiti gunshot wound patient receiv recel soc defin telfa clear xeroform wound dress intervent patient whose wound result burn fail heal follow surgic intervent exclud studi recel system combin mesh autograft reduct donor skin harvest soft tissu reconstructiontitl rcel outperform
mention believ surgeon alreadi use recel off-label
basi certain level trauma center either also treat burn affili
burn center financi forecast pool burn trauma wound patient
inpati procedur break-out trauma revenu achiev inpati
forecast usd like requir mean uptak soft tissu
point refer roughli burn center surgeon us
forecast assum inpati clinician train use recel averag roughli
take rcel like need train surgeon trauma wound reach
exhibit address market million trauma injuri
mention expect burn center pay recel drg
payment inpati care inpati care extens burn bundl singl
reimburs medicar includ code present
exhibit medicar reimburs hospit inpati servic use ms-drg
exhibit common ms-drg patient admit burn treatment recel system
addit believ may flexibl reimburs trauma patient
code harvest skin sampl applic cell
suspens autograft rcel suggest hospit use follow code harvest
traumat wound marketpati hospit wound treat level trauma center growth avita medic ltd
follow code autograft gener appli recel
global surgeri indic major surgeri preoper period post-operative period includ fee schedul
amount yyy carrier determin whether global concept appli establish post-operative period appropri time
price zzz code relat anoth servic alway includ global period servic
take seek reimburs exist autograft reimburs cover
portion cost recel believ establish separ ambulatori
payment code apc reimburs code may necessari commerci
product outpati set
current reimburs vitiligo depend type treatment administ
accord reimburs bulletin aetna medic necessari treatment
vitiligo includ excim laser narrow-band ultraviolet uvb topic oral
psoralen photochemotherapi puva topic tacrolimu topic system
exhibit sampl code approv vitiligo treatment
treatmentcod phototherapi light therapi excim laser uvb oral psoralen photochemotherapi puva tacrolimusmultipl begin jtopic system corticosteroidsmultipl begin rcel outperform
solut use recel contain mix popul cell includ
keratinocyt fibroblast melanocyt keratinocyt fibroblast
particularli import acceler heal pilot studi demonstr melanocyt
recel may effect treat depigment disord vitiligo
take treatment depigment use recel devic workflow
commerci may requir modif devic buffer payment
model specif reimburs code commerci opportun limit
patient background medic stabil diseas unlik appropri
patient progress diseas
posit pilot studi recel vitiligo
pilot studi five patient stabl segment vitiligo five patient
piebald unpig tissu hairlin median repigment
section treat recel cst-ced compar control no-
treatment control site friedman test exhibit
komen et al autolog cell suspens transplant use cell extract devic segment vitiligo piebald patient random control pilot
studi journal american academi dermatolofi
compani also conduct field studi china publish
journal dermatolog treatment studi liu et al observ
month follow-up patient show good respons among
respond roughli show complet almost complet repigment
studi use dilut recel upper limit dilut
evalu on-going us dose rang vitiligo studi
liu et al clinic efficaci treatment use autolog non-cultur epiderm cell suspens techniqu stabl vitiligo patient journal
interestingli four children show good respons
repigment furthermor signific differ efficaci
treatment differ transplant area
take pilot studi de-risk futur develop particularli given poor perform
altern treatment option repigment
on-going us pilot studi support registr strategi
compani recent began recruit random studi
within-subject control compar recel ultraviolet lamp uva activ control
melanocyte-keratinocyt transplant procedur mktp uva intervent
studi evalu match stabl depig area patient
subject must year age focal segment gener vitiligo
document stabl new lesion lesion expand size within preced
month undergon prior treatment within day enrol
subject universali vitiligo koebner phenomenon and/or confetti-lik lesion known
hypersensit trypsin compound sodium lactat irrig solut exclud
studi
describ exhibit rcel evalu three differ concentr cell
select best dose registr studi preclin model suggest dilut
vitiligo compar burn patient due lower concentr melanocyt
skin harvest howev chines studi referenc achiev encourag
result dilut on-going us studi evalu preclin recommend
dose dose chines studi middl dose
exhibit overview studi arm intervent
primari endpoint repigment determin percent area repig
studi area week assess blind evalu
take believ vitiligo studi vulner delay relat
cautious optimist rcel enrol small ten-pati studi time
secondari endpoint includ respond determin proport treat
lesion achiev moder mark excel
repigment patient repigment rate rate poor moder good
excel blind evalu color match also scale poor
excel inclus hypopigment hyperpigment secondari
endpoint assess week
vitiligo often autoimmun disord character skin depigment uneven
patchi segment pathogenesi vitiligo fulli understood exhibit
provid overview potenti mechan pathogenesi
studi armintervention/treatmentno intervent controlarea without surgic interventionexperiment recel recel ultraviolet lamp uva experiment recel recel ultraviolet lamp uva experiment recel recel ultraviolet lamp uva regen epiderm suspens dilut appli surgic prepar area depigmentationskin cell suspens dilut prepar use recel system appli surgic prepar area depigmentationregen epiderm suspens dilut appli surgic prepar area depigmentationskin cell suspens dilut prepar use recel system appli surgic prepar area depigmentationregen epiderm suspens dilut appli surgic prepar area depigmentationskin cell suspens dilut prepar use recel system appli surgic prepar area depigmentationact compar melanocyte-keratinocyt transplantationprocedur melanocyte-keratinocyt transplant ultraviolet lamp uva autolog skin cell suspens prepar laboratori base melanocyte-keratinocyt transplant procedur techniqu appli surgic prepar area depigmentationappl melanocyt aka melanocyte-keratinocyt transplant procedur mktp surgic prepar depig area avita medic ltd
exhibit pathogenesi nonsegment vitiligo
furu kadono nonsegment vitiligo updat dermatologica sinica
depig skin lack melanocyt becom apoptot variou
condit due upregul cell interferon- e-cadherin loss
express elev oxid stress releas reactiv oxygen speci ro
activ langerhan may facilit cellular humor immun
disord may genet genet mutat link vitiligo
susceptibilitybut patient present known genet risk factor
vitiligo clinic presentationfocu segment
vitiligo symptom categor segment non-segment mix
segment diseas typic cross midlin bodi spread quickli
often associ autoimmun diseas segment diseas tend also
stabliz quickli non-segment diseas view make patient
good potenti candid recel preval segment diseas rang
epidemiolog studi exhibit
ezzedin et al revis classification/nomenclatur vitiligo relat issu vitiligo global issu consensu confer pigment cell melanoma research
definit diseas stabil vitiligo issu on-going debat review titl
stabil vitiligo perfect way predict publish journal
cutan aesthet surgeri sahni parsad note littl consensu
criteria defin stabil clinic present appear wide use metric
biochem ultrastructur correl use well furthermor
consensu minimum period static diseas present exhibit
formdescriptionestim prevalencecharacter unilater distributionsegmentalcharacter symmetr bilater white includ mix present rcel outperform
take establish clearer consensu minimum period static diseas
classifi vitiligo patient stabl would like benefit commerici uptak clinic
outcom recel
exhibit definit vitiligo stabil vari year
sahni parsad stabil vitiligo perfect way predict journal cutan aesthet surgeri
accord american academi dermatolog american sought
treatment vitiligo exhibit repres roughli peopl present
symptom disord assum nation preval rate
exhibit number peopl receiv treatment dermatolog condit
american academi dermatolog skin diseas brief
base part pilot studi non-segment vitiligo termin due futil
expect develop focu segment vitiligo estim
patient roughli subject appli treatment rate referenc
non-segment segment patient arriv popul
take expect address vitiligo market expand next year
treatment option extend portion market seek treatment current rate
portion treat patient achiev stabl diseas treat
authorsyearperiod stabil da pasricha monthsboersma monthsjha et yearsingh yearsfalabella yearsfalabella et al year avita medic ltd
forecast focus us market believ signfic opportun
variou ex us market cash pay basi highlight exhibit vitiligo
preval rate vari region larger concentr part scandanvia
exhibit global preval vitiligo base publish studi
kruger et al review world-wide preval vitiligo children/adolesc adult intern journal
take could upsid outlook new topic therapi jak
inhibitor improv rate stabl diseas autoimmune-medi vitiligo forecast
conserv estim non-segment vitiligo autoimmun compon
contribut progress depigment new topic therapi provid durabl
suppress autoimmune-medi depigment non-segment patient
could candid melanocyt replac therapi recel
current treatment option vitiligo
current vitiligo patient treat combin non-surg surgic
treatment exhibit present therapeut algorithm vitiligo summar
immunomodulator-bas phototherapi topic steroid first-lin therapi
chronic use associ skin atrophi teleangiectasia hypertrichosi acneiform
erupt striae immunomodulator-bas applic appear less effect
though side effect less common
vitiligo vitiligo rcel outperform
oral corticosteroid shown halt rapid progress vitiligo use
regul due known long-term side effect includ weigh gain sleep disturb
agit acn hypertrichosi
exhibit therapeut algorithm vitiligo
cs corticosteroid nb narrow band puva psoralen uva tim topic immunomodul uv ultraviolet
ruxolitinib cream effect halt vitiligo progess exhibit provid
overview jak-stat signal pathway relat vitiligo pathogenesi
jak-stat pathway critic control activ inflammatori cytokin
growth hormon activ jaki/ii phosphoryl stat lead dimer
transloc nucleu gene transcript
take success phase develop commerci jak inhibitor
stabil vitiligo would expand market recel among non-segment patient
solimani et al emerg topic system jak inhibitor dermatolog frontier immunolog
furthermor chemokin profil reveal depig patch skin high
signatur promot recruit t-
cell epidermi may damag melanocyt
phase ii studi explor four differ dose cohort daili
twice daili topic treatment ruxolitinib cream studi design present
exhibit incyt phase ii studi ruxolitinib overview
ruxolitinib cream met primari endpoint improv facial assess
vitiligo area sever index score week exhibit
exhibit incyt phase ii studi ruxolitinib overview
furthermor percentag patient receiv ruxolitinib cream bid
achiev increas week addit f-
improv baselin f-vasi score achiev
patient treat ruxolitinib cream bid week
compar patient control week respect
februari enrol first patient phase studi topic ruxolitinib
phototherapi often second-lin treatment control depigment depigment
continu month treatment clinician recommend discontinu
phototherapi procedur associ improv depigment
take jak inhibitor opportun replac phototherapi second-lin
surgic method consist graft techniqu depig treatment
appropri sever patient patient achiev prolong stabl diseas
prior treatment specif depig treatment consid subject
sever refractori vitiligo cover tbsa graft tissu full
thick split thick suction-blist cell cultur melanocyt non-
cultur epiderm cell surgic method effect segment
vitiligo stabl non-segment vitiligo
take recel opportun replac skin graft surgic method
scaldspath pediatr label
collabor barda rcel initi two pediatr studi design studi
efficaci safeti recel pediatr wound heal scald separ
studi trauma injuri anticip result studi recapitul
posit data adult burn patient pediatr pilot studi howev believ
timelin complet enrol could protract program due
challeng enrol pediatr subject co-administr barda
take recel approv patient year age older believ
product alreadi use label pediatr patient pediatr scald studi offer
opportun gain label indic pediatr limit expens compani
background pediatr scald
pediatr case account case treat burn center accord
aba report among burn case scald second common etiolog
repres case exhibit
exhibit etiolog burn center case
furthermor scald account disproportion number pediatr case vs
exhibit frequenc burn etiolog group
scald registr studi ongoingdata
march rcel open enrol studi scald patient age
year studi design demonstr potenti autograft spare time-
to-wound heal compar mepilex wound dress studi enrol pediatr
patient burn cover tbsa tbsa full-thick burn
patient whose burn result chemic electr radiat patient
degree/full-thick exclud studi
patient treat either recel mepilex wound dress autograft
perform deem necessari treat surgeon
co-primari endpoint requir convent autograft measur
number index burn area requir autograft post-treat
index burn area heal time number day heal week
secondari endpoint includ index burn area heal time recel compar
control pain measur scale worst pain imagin
week outcom
outcom measur includ need convent autograft day scar
rate use patient observ scar assess scale posa
worst scar imagin qualiti life outcom captur via age specif burn
outcom questionnair boq interv investig treatment prefer
health economics/med resourc util
overview barda contract
term agreement barda cover seri discret work order
aggreg valu decemb compani receiv
includ initi invest support rcel us clinic
regulatori program exhibit present overview base statement
exhibit summari barda statement work recel
contract call barda purchas recel devic option
surg capac anoth devic option exercis septemb
includ work vulner popul children addit contract option
establish fund clinic health econom research us pediatr burn care
term option rcel barda expand origin contract
addit support two pediatr studi exhibit present
overview addit option
treat chronic wound dfu vlu among largest segment
wound care market continu expand incid underli morbid
diabet metabol syndrom increas due age popul
increas rate obes believ recel like find nich larg
market believ reimburs model well defin subset
candid autolog cell therapi may benefit small full-thick graft
current includ econom indic financi outlook
take chronic wound larg secondari market recel requir differ
commerci model potenti need multipl clinic trial support reimburs
subject open leg ulcer recruit six site england one site
franc juli novemb subject clinic assess
anklebrachi pressur index abpi measur confirm elig
ulcer defin use comprehens ceap clinic aetiolog anatomi
pathophysiolog classif system ulcer also need present least four
week area expos tendon bone
total subject recruit subject enrol screen exhibit
endpoint includ incid complet wound closur donor site closur
pain healthrel qualiti life hrqol safeti
hay et al pilot multicent prospect random control trial recel treatment venou ulcer intern wound journal
week vlu treat recel asc compress statist greater
decreas ulcer area compar control versu
decreas ulcer size seen earli week exhibit week larger
ulcer higher mean percentag reepitheli
recel compress control
exhibit recel facilit wound closur averag repres case studi
hay et al pilot multicent prospect random control trial recel treatment venou ulcer intern wound journal
rcel complet dfu feasibl studi juli single-arm
observ studi includ patient treat three hospit unit kingdom
site includ manchest royal infirmari king colleg hospit northwick
park hospit patient enrol studi chronic dfu rang size
 patient fail heal soc treatment
result studi includ patient experienc reduct dfu
wound size averag wound size reduct week
patient complet wound closur median time-to-h week
forecast assum limit direct competit three primari autolog
skin cell therapiesrecel epicel skint
believ recel posit serv market tbsa wound
focu tbsa base eas use spray applic faster
manufactur turnaround time rel epicel attract cog term
posit epicel expect product remain gold standard larg wound
label intend use tbsa base potenti produc larg sheet
patient skin autograft alon option view skint best
posit use chronic wound market combin modal
treatment burn patient believ skint demonstr potenti
produc high qualiti skin inabl produc rapid steril cover may limit uptak
burn patient primari goal first creat steril environ prevent
infect follow secondari focu optim heal consid
cellmist viabl commerci competitor due limit clinic data exhibit
provid overview regen cell therapi treatment burn acut
exhibit overview regen skin product
companyproductindicationnotesavita medic recel superfici partial thicknessrenovacar cellmist/skingun deep partial-thick burn deep partial full full cell collect via biopsi cultur cell collect via biopsi imprint use system laboratori cultur laboratori mice cell point-of-car rcel outperform
revenu
us recel revenu model segment demand inpati outpati market
base differ reimburs model potenti differ workflow
requir nearli recel demand current inpati market
forecast call faster growth outpati market begin due demand
vitiligo patient total forecast recel sale
inpati outpati compar figur
australian dollar total sale inpati
outpati
peopl hospit burn annual accord american burn
associ registri view burn patient tbsa best candid
inpati treatment recel market roughli patient annual
treatment trauma wound particularli level trauma center larger
address market case annual grow
total view address inpati market patient
develop recel outpati use reimburs coverag
expect treatment outpati set increas outlook focus two
segment outpati market burn patient tbsa vitiligo
total estim outpati popul patient split vitiligo
tbsa wound expect market grow
forecast assum canist recel result usd
recogn revenu compani patient treat recel requir averag
canist blend averag revenu per patient usd
expect compani sell recel us recogn revenu
exhibit us recel revenu model australian dollar
inpati market patient tbsa burn level trauma center recel inpati outpati market patient vitiligo recel outpati utilization- patient treat inpati devic sold per inpati patient patient treat outpati devic sold outpati per patient outpati patient price per revenu per inpati procedur outpati procedur recel revenu inpatient/outpati avita medic ltd
exhibit us recel revenu model us dollar
rcel manag disclos number metric track revenu growth
forecast assum slowdown newli train physician canist use
physician fiscal disloc associ
inpati market patient tbsa burn level trauma center recel inpati outpati market patient vitiligo recel outpati utilization- patient treat inpati devic sold per inpati patient patient treat outpati devic sold outpati per patient outpati patient price per revenu per inpati procedur outpati procedur recel revenu inpatient/outpati conversaion rate april australian dollar us dollar convers indic patient tbsau oper metric burn burn center order recel cumul chang physician train recel cumul burn center chang physician train per order burn center per order burn center per train physician burn center per recel canist price increasenumb canist per train physician number canist per number patient treat rate april australian dollar us dollar convers rcel outperform
figur provid gener overview oper metric underli
revenu forecast outpati market driven demand vitiligo patient
gener expect outpati set use fewer unit recel annual
per clinician basi practic roughli one-third number clinician
train recel view market fragment inpati
us oper metric outpati order recel cumul chang physician train recel cumul outpati chang physician train per order center per recel canist canist per train physician number canist per number patient treat rate april australian dollar us dollar convers avita medic ltd
overview epidermolysi bullosa eb
eb phenotyp divers group inherit skin order present autosom
domin autosom recess form patient recess dystroph eb rdeb
form diseas typic present sever blister skin larg area
lead loss function poor qualiti life mortal subject autosom
domin dystroph eb ddeb typic present local diseas hand
feet knee joint result defect type vii collagen anchor skin
place form diseas includ epidermolysi bullosa simplex
loss function encod protein anchor extern epithelia
underli stroma common among eb subtyp popular target
take rcel identifi target eb popul believ spray-on
formul would particularli well suit ddeb patient local symptom
joint amen skin graft
exhibit genet divers eb
uitto et al progress toward treatment cure epidermolysi bullosa summari debra intern research symposium journal
clinic symptom eb
subject typic present symptom eb newborn young children
chronic condit result fragil skin suscept blister follow minim trauma
condit often refer butterfli skin popular media review entitl
epidemiolog inherit epidermolysi bullosa base incid preval
estim nation epidermolysi bullosa registri analyz data
patient consecut enrol nation epidermolysi bullosa registr nebr
septemb april author calcul incid us
patient per one million life birth us patient annual exhibit
exhibit incid preval eb us
fine jo-david epidemiolog inherit epidermolysi bullosa base incid preval estim nation epiderm olysi bullosa registri
journal american medic associ jama
uitto et al articl journal investig dermatolog provid
comprehens discuss avail emerg treatment option view
still applic exhibit summar find articl entitl progress
toward treatment cure epidermolysi bullosa summari debra
exhibit molecular pharmacolog approach treatment eb
ct clinic trial initi on-going recent complet pc approach test preclin studi often util appropri mous model eb ps test
drug plan stage bmt bone marrow transplant prematur termin codon nmd nonsense-medi mrna decay
uitto et al progress toward treatment cure epidermolysi bullosa summari debra intern research symposium journal
view topic beremagen geperpavec
provid benchmark minimum eb efficaci profil rcel program
potenti templat clinical/regulatori strategi
topic beremagen geperpavec commonli known
complet phase phase ii studi treatment dystroph epidermolysi
bullosa rdeb gene therapi transduc keratinocyt fibroblast
transduc b-vec enter nucleu mediat transcript healthi function
control product protein anchor fibril
extern epithelia underli stroma overview mechan
action present exhibit
exhibit topic beremagen geperpavec mechan action
june krystal disclos interim result gem studi two pediatr
two adult patient rdeb treatment appli three wound size
patient one adult patient age voluntarili drop phase ii portion
due inabl commit treatment leav total six wound treat b-
primari endpoint wound closur week post-treat defin chang
wound surfac area rel baselin placebo time wound closur rel
placebo durat wound closur rel placebo
pool analysi phase phase ii studi seven eight wound treat
close wound heal chronic wound
persist four year partial close day time point
compar none placebo treat wound close fulli studi
prevent comparison wound closur time placebo
furthermor phase studi durat wound closur two patient follow
wound closur day month day month june
averag durat wound closur time point phase ii studi
recur wound day median day
krystal also evalu presenc collagen vii presenc anchor fibril
investig measur function stain tissu sampl antibodi
bind domain protein respect skin biopsi
reveal presenc domain indic success product
function linearli line along basement membran zone bmz
take see opportun rcel spray-on gene therapi treat joint
high-contact area believ product could enjoy gener use re-
epitheli record shorter time frame krystal product
less week
view partnership central rcel busi model expect
compani reli primari intern resourc product develop us
univers colorado school medicinecel theray research agreement
novemb rcel scientist gate center regen medicin
univers colorado school medicin sign preclin research collabor
develop spray-on treatment genet modifi cell patient use
epidermolysi bullosa eb genet skin disord disclosur scope
